Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab

Publish date:: December 11, 2020

Key clinical point: Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with sequential blinatumomab is highly effective as frontline therapy for Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.

Major finding: Relapse-free survival at 1- and 2-years was 80% and 71%, respectively, with frontline hyper-CVAD and blinatumomab.

Study details: The phase 2 study included 38 patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.

Disclosures: Dr. Short reported consulting with Takeda Oncology and Astrazeneca, and receiving research funding and honoraria from Amgen, Astella, and Takeda Oncology.

Citation:

Short NG et al. ASH 2020, Abstract 464.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,